IP Library Granted Patent US 8,697,860
Granted Patent B1
US 8,697,860 · App. 13/944,786 · Granted Apr 15, 2014

Diagnosis and treatment of disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,697,860
App. No.
13/944,786
Granted
Apr 15, 2014
Kind
B1
Abstract

Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.

Claims (20)

1. A composition comprising an aqueous solution having a viscosity level less than 40 centipoise (cP), wherein the aqueous solution comprises a compound comprising a single-stranded modified oligonucleotide consisting of 20 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 80, wherein the modified oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5′ wing segment consisting of five linked nucleosides; and

a 3′ wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment, wherein each nucleoside of each wing segment comprises a 2′-O-methoxyethyl sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine of the modified oligonucleotide is a 5-methylcytosine.

2. The composition of claim 1 , wherein the aqueous solution has a temperature of about 25° C.

3. The composition of claim 2 , wherein the aqueous solution consists of water and the compound.

4. The composition of claim 1 , wherein the aqueous solution has a viscosity level less than 15 centipoise (cP).

5. The composition of claim 4 , wherein the aqueous solution has a temperature of about 25° C.

6. The composition of claim 5 , wherein the aqueous solution consists of water and the compound.

7. The composition of claim 4 , wherein the aqueous solution consists of water and the compound.

8. The composition of claim 1 , wherein the aqueous solution has a viscosity level less than 12 centipoise (cP).

9. The composition of claim 8 , wherein the aqueous solution has a temperature of about 25° C.

10. The composition of claim 9 , wherein the aqueous solution consists of water and the compound.

11. The composition of claim 8 , wherein the aqueous solution consists of water and the compound.

12. The composition of claim 1 , wherein the aqueous solution has a viscosity level less than 10 centipoise (cP).

13. The composition of claim 12 , wherein the aqueous solution has a temperature of about 25° C.

14. The composition of claim 13 , wherein the aqueous solution consists of water and the compound.

15. The composition of claim 12 , wherein the aqueous solution consists of water and the compound.

16. The composition of claim 1 , wherein the aqueous solution consists of water and the compound.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2018
From: GUO, SHULING
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 047558/0123 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2018
From: MONIA, BRETT P.; FREIER, SUSAN M.; SIWKOWSKI, ANDREW M.
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 047457/0418 →
CHANGE OF NAME Recorded Jun 15, 2017
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 042832/0349 →